ARC has a Fucoidan based product, PERIDAN® Concentrate, for the reduction of surgical adhesions in horses, foals and rabbits. This propriety liquid medical device consists of a sulphated, high molecular weight polysaccharide in a physiological salt solution. PERIDAN® Concentrate is administered at the end of a surgical procedure immediately prior to the final closing of the surgical site. PERIDAN® Concentrate has been shown in clean and clean-contaminated foal and horse surgical studies to safely reduce the number and strength of post-surgical adhesions. Visit www.peridan.com.
PERIDAN® Concentrate is in early preclinical testing for the human market.
ARC’s product has two competitive advantages:
The mechanism of action of PERIDAN® Concentrate in the prevention of the formation of adhesions is thought to be due to the products’ physical form. These medical devices provide a barrier and prevent adhesions from forming. These products separate the tissue surfaces during the early stages of tissue repair with a coating of polymer (PERIDAN®) remaining on the surfaces.
For information on ARC research studies click here.